Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.56 USD | +3.49% | +20.68% | +148.95% |
Apr. 23 | Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market | CI |
Apr. 09 | Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating | MT |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- With an expected P/E ratio at 890 and 61.91 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+148.95% | 260M | C- | ||
+1.77% | 42.75B | B | ||
+47.70% | 41.61B | A | ||
+12.24% | 41.34B | B- | ||
-8.83% | 26.59B | C | ||
+7.44% | 25.49B | B- | ||
-23.01% | 18.12B | B | ||
+30.56% | 12.24B | C+ | ||
-1.82% | 11.76B | C+ | ||
+8.35% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CDXC Stock
- Ratings ChromaDex Corporation